Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AC-73 是一种可口服的 Cluster of Differentiation 147 (CD147) 抑制剂,具有很高的生物利用,可选择性破坏 CD147 的二聚化 (结合位点在 CD147 的 N 端 IgC2 域中包括 Glu64 和 Glu73),从而对 CD147/ERK1/2/STAT3/MMP-2 途径产生抑制,并抑制肝癌细胞的运动和侵袭。AC-73 具有抗增殖活性,诱导白血病细胞自噬。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 413 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,830 | 现货 | ||
25 mg | ¥ 3,380 | 现货 | ||
50 mg | ¥ 5,390 | 现货 | ||
100 mg | ¥ 7,380 | 现货 | ||
500 mg | ¥ 14,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | AC-73 is an orally available Cluster of Differentiation 147 (CD147) inhibitor with high bioavailability that selectively disrupts the dimerization of CD147 (the binding site is in the N-terminal IgC2 domain of CD147 including Glu64 and Glu73), resulting in inhibition of the CD147/ERK1/2/STAT3/MMP-2 pathway and inhibition of liver cancer cell motility and invasion. AC-73 has antiproliferative activity and induces autophagy in leukemia cells. |
体外活性 |
AC-73 (5-10 μM; 24 hours; SMMC-7721 and Huh-7 cells) treatment results in a dose-dependent reduction in the migration ability of SMMC-7721 and Huh-7 cells, as well as a dose-dependent decrease in the invasion of these two HCC cell lines at 24 hours. AC-73 treatment leads to a reduction in HCC metastasis. When treating the two HCC cell lines with AC-73 at a maximum concentration of 20 μM, there are no significant effects on cell viability. AC-73 potentially binds to CD147 at Glu64 and Glu73 in the N-terminal IgC2 domain, where both residues are situated within the dimer interface of CD147.[1] AC-73 (5-10 μM; 24 hours; SMMC-7721 cells), at a concentration of 10 μM, significantly inhibits the mRNA expression of both MMP-2 and MMP-9, with a more pronounced effect on MMP-2, while demonstrating no discernible impact on MMP-1, MMP-3, MMP-7, MMP-11, or MMP-13. AC-73 exhibits a dose-dependent reduction in MMP-2 mRNA levels and protein secretion, as confirmed through RT-qPCR analysis and gelatin zymography experiments.[1] AC-73 (5-20 μM; 6 hours; SMMC-7721 cells), in a dose-dependent manner, attenuates the phosphorylation of ERK1/2 and STAT3.[1] |
体内活性 | AC-73 (25-50 mg/kg; Injected; daily; for 3 weeks; Male BALB/c nu/nu mice with SMMC-7721 cells) treatment significantly decreases the incidence of metastatic foci in nude mice. AC-73 inhibits the phosphorylation of ERK1/2 and STAT3 in a dose-dependent manner. MMP-2 is also reduced by AC-73. AC-73 could not inhibit tumor cell proliferation in vivo.[1] |
分子量 | 319.4 |
分子式 | C21H21NO2 |
CAS No. | 775294-71-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (313.09 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1309 mL | 15.6544 mL | 31.3087 mL | 78.2718 mL |
5 mM | 0.6262 mL | 3.1309 mL | 6.2617 mL | 15.6544 mL | |
10 mM | 0.3131 mL | 1.5654 mL | 3.1309 mL | 7.8272 mL | |
20 mM | 0.1565 mL | 0.7827 mL | 1.5654 mL | 3.9136 mL | |
50 mM | 0.0626 mL | 0.3131 mL | 0.6262 mL | 1.5654 mL | |
100 mM | 0.0313 mL | 0.1565 mL | 0.3131 mL | 0.7827 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AC-73 775294-71-8 Autophagy AC 73 AC73 Inhibitor inhibitor inhibit